Supplementary Materials:


Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record

Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis and Giancarlo Troncone

Table S1. Original PD-L1 evaluation, expert board consensus and prevalent scoring for every group; discrepancies between the original evaluation and the panel are highlighted in orange; participants errors in yellow.

CASES	ORIGINAL INSTITUTION	EXPERT BOARD	ORANGE	RED	VIOLET	GREEN	PINK	BLUE	YELLOW
1	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
2	≥50%	≥50%	<mark>1-49%</mark>	≥50%	≥50%	≥50%	≥50%	≥50%	<mark>1-49%</mark>
3	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<mark>1-49%</mark>	<1%
4	1-49%	1-49%	<mark><1%</mark>	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
5	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
6	<1%	<1%	<1%	<mark>1-49%</mark>	<mark>1-49%</mark>	<1%	<mark>1-49%</mark>	<1%	<mark>1-49%</mark>
7	1-49%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
8	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
9	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	1-49%	<mark><1%</mark>
10	<1%	<1%	<1%	<mark>1-49%</mark>	<1%	<1%	<1%	<1%	<1%
11	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	<1%	<mark><1%</mark>
12	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
14	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
15	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
16	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
17	1-49%	1-49%	<mark><1%</mark>	1-49%	1-49%	1-49%	1-49%	<1%	1-49%
20	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
22	1-49%	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
30	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%
33	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
34	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%	≥50%
35	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%
36	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<1%	<mark>1-49%</mark>
37	≥50%	≥50%	<mark>1-49%</mark>	<mark>1-49%</mark>	<mark>1-49%</mark>	<mark>1-49%</mark>	≥50%	<mark>1-49%</mark>	≥50%
38	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
41	<1%	1-49%	1-49%	1-49%	1-49%	1-49%	<1%	1-49%	1-49%
45	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%
50	≥50%	1-49%	1-49%	<mark>≥50%</mark>	1-49%	1-49%	<mark>≥50%</mark>	<mark>≥50%</mark>	1-49%
51	≥50%	1-49%	<mark>≥50%</mark>	<mark>≥50%</mark>	1-49%	1-49%	1-49%	<mark>≥50%</mark>	<mark>≥50%</mark>
52	≥50%	1-49%	1-49%	<mark>≥50%</mark>	<mark>≥50%</mark>	<mark>≥50%</mark>	1-49%	≥50%	1-49%
54	<1%	1-49%	1-49%	<mark>≥50%</mark>	1-49%	1-49%	1-49%	1-49%	1-49%
55	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%	1-49%

Table S2. Participant performances. In the columns, the cases of the study were grouped from negative (green, TPS< 1%) to strong positive (red, TPS ≥50%). In the first row, the gold standard results recorded by the board of experts were listed. In the following rows, for every pathologist who attended the meeting a progressive number and a colour of identification corresponding to the table were assigned. (ie.e R1: red table, participant number 1).






Table S3. Performances by histotype.

-	R(n=5)	Y (n=5)	O (n=5)	V(n=5)	B (n=6)	P(n=6)	G(n=5)		
-	Adenocarcinoma (n = 22)								
1	>			<	<		<		
2									
4	<		<(3)		>(1);<(1)	<			
5									
6									
7									
9		<(3)	>		<		<(3)		
10									
11	<(1);>(1)	<(4)	<(2)	<	<(4)	<(2)	<(5)		
12			>				>(2)		
14									
15									
22									
30									
34									
35									
36									
41						<(5)			
50	>(3)	>(2)	>(2); <(1)		>(4)	>(4)	>(2)		
52	>(4)			>(5)	>(3)	>(2)	>3		
54	>(4)					>(1); <(1)			
55	>								
		Squamo	us cell carcinon	1a / NSCLC, NO	OS (n = 10)				
3									
8									
16	>				>		>		
17	<		<(3)		<(4)		<(2)		
20									
33	>								
37									
38				<			<(2)		
45									
51	>(5)	>(3)	>(3); <(1)		>(5)	>(2)	>		

Table S4. Performances by clone.

	R(n=5)	Y (n=5)	O (n=5)	V(n=5)	B (n=6)	P(n=6)	G(n=5)			
22C3 (n = 23)										
1	>			<	<		<			
2										
3										
4	<		<(3)		>(1);<(1)	<				
5										
6										
7										
8										
9		<(3)	>		<		<(3)			
10										
11	<(1);>(1)	<(4)	<(2)	<	<(4)	<(2)	<(5)			
12			>				>(2)			
14										
15										
16	>				>		>			
17	<		<(3)		<(4)		<(2)			
20										
22										
33	>									
34										
35										
54	>(4)					>(1); <(1)				
55	>									
	·		SP2	.63 (n = 9)						
30										
36										
37										
38				<			<(2)			
41						<(5)				
45										
50	>(3)	>(2)	>(2); <(1)		>(4)	>(4)	>(2)			
51	>(5)	>(3)	>(3); <(1)		>(5)	>(2)	>			
52	>(4)			>(5)	>(3)	>(2)	>3			